haloperidol has been researched along with Serotonin Syndrome in 8 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Serotonin Syndrome: An adverse drug interaction characterized by altered mental status, autonomic dysfunction, and neuromuscular abnormalities. It is most frequently caused by use of both serotonin reuptake inhibitors and monoamine oxidase inhibitors, leading to excess serotonin availability in the CNS at the serotonin 1A receptor.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The Naranjo probability scale indicated probable causality for NMS due to quetiapine, haloperidol, and risperidone in this patient, whereas the Naranjo scale assigned only possible causality for serotonin syndrome developing with serotonergic agents." | 3.77 | Neuroleptic malignant syndrome versus serotonin syndrome: the search for a diagnostic tool. ( Ariano, RE; Sokoro, AA; Zivot, J, 2011) |
| " blood pressure, heart rate, body temperature) can be reduced, possibly due to a pharmacodynamic interaction at the serotonin reuptake transporter (SERT)." | 2.48 | Pharmacokinetics and pharmacodynamics of 3,4-methylenedioxymethamphetamine (MDMA): interindividual differences due to polymorphisms and drug-drug interactions. ( Hondebrink, L; Meulenbelt, J; Rietjens, SJ; Westerink, RH, 2012) |
| "Rats treated with haloperidol at a dose of 1 mg/kg twice a day for 2 weeks displayed VCMs with twitching of facial musculature that increased in a time dependent manner as the treatment continued to 5 weeks." | 1.34 | Reversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats. ( Haleem, DJ; Haleem, MA; Samad, N, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Prakash, S | 1 |
| Lodha, D | 1 |
| Rawat, KS | 1 |
| Iderberg, H | 1 |
| McCreary, AC | 1 |
| Varney, MA | 1 |
| Kleven, MS | 1 |
| Koek, W | 1 |
| Bardin, L | 1 |
| Depoortère, R | 1 |
| Cenci, MA | 1 |
| Newman-Tancredi, A | 1 |
| Suzuki, K | 1 |
| Batool, F | 1 |
| Haleem, DJ | 2 |
| Steele, D | 1 |
| Keltner, NL | 1 |
| McGuiness, TM | 1 |
| Sokoro, AA | 1 |
| Zivot, J | 1 |
| Ariano, RE | 1 |
| Rietjens, SJ | 1 |
| Hondebrink, L | 1 |
| Westerink, RH | 1 |
| Meulenbelt, J | 1 |
| Samad, N | 1 |
| Haleem, MA | 1 |
1 review available for haloperidol and Serotonin Syndrome
| Article | Year |
|---|---|
Pharmacokinetics and pharmacodynamics of 3,4-methylenedioxymethamphetamine (MDMA): interindividual differences due to polymorphisms and drug-drug interactions.
Topics: Animals; Blood Pressure; Body Temperature; Brain; Carbazoles; Carvedilol; Cytochrome P-450 CYP2D6; D | 2012 |
7 other studies available for haloperidol and Serotonin Syndrome
| Article | Year |
|---|---|
Coexistence of serotonin syndrome and neuroleptic malignant syndrome: does it exist?
Topics: Adult; Antipsychotic Agents; Haloperidol; Humans; Male; Neuroleptic Malignant Syndrome; Risperidone; | 2021 |
NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Brain; Catalepsy; Disease Models, Animal; Drug Int | 2015 |
[Three cases of acute serotonin syndrome due to psilocybin mushroom poisoning].
Topics: Acute Disease; Adult; Agaricales; Aged; Charcoal; Diazepam; Female; Fluid Therapy; Haloperidol; Huma | 2016 |
Serotonin(1A) receptor agonism in the expression of behavioral dopaminergic supersensitivity in subchronic haloperidol treated rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Basal Ganglia Diseases; Behavior, Animal; Brain; Di | 2008 |
Are neuroleptic malignant syndrome and serotonin syndrome the same syndrome?
Topics: Antidepressive Agents, Tricyclic; Antipsychotic Agents; Dibenzothiazepines; Drug Therapy, Combinatio | 2011 |
Neuroleptic malignant syndrome versus serotonin syndrome: the search for a diagnostic tool.
Topics: Antipsychotic Agents; Catecholamines; Diagnosis, Differential; Dibenzothiazepines; Dopamine; Female; | 2011 |
Reversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Buspirone; Chromatography, Hi | 2007 |